KIT and myocardial infarction: In conclusion, our findings suggest that AT2R partly ameliorates the c-kit+ bone marrow precursor cell functions in supporting cardiomyocyte performance in response to MI and, thus, may provide a new strategy to improve stem cell therapeutic effects.